Evaluation of adherence, persistence and efficacy of treatment with alirocumab 300 mg in a real-life Italian population.
Study Type
OBSERVATIONAL
Enrollment
1,500
Alirocumab 300 mg injection
Federico II University of Naples, Department of Advanced Biomedical Sciences
Naples, Napoli, Italy
RECRUITINGDescription of adherence of treatment with alirocumab 300mg in a real-life Italian population.
Adherence will be assessed in terms of Medical Possession Ratio (MPR) which is defined as the ratio between the treatment units dispensed during the treatment period and the duration of the treatment period itself.
Time frame: 6-12-24-36 months
Description of persistence of treatment with alirocumab 300mg in a real-life Italian population.
Persistence will be assessed in terms of therapeutic continuity from the start of treatment to enrollment.
Time frame: 6-12-24-36 months
Description of efficacy of treatment with alirocumab 300mg in a real-life Italian population.
Efficacy of treatment will be evaluated as a change in the LDL (deltaLDL) value from the start of treatment (percentage and absolute value).
Time frame: 6-12-24-36 months
Description of safety of treatment with alirocumab 300mg in a real-life Italian population.
Safety will be evaluated in terms of adverse reactions or intolerance to the drug.
Time frame: 6-12-24-36 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.